Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy

Lee, Derek; Rosenthal, Carl J.; Penn, Natalie E.; Dunn, Zachary Spencer; Zhou, Yang; Yang, Lili

doi:10.3390/cancers14123005

Cited by 25 publications

(23 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…gov). In addition to conventional T cells, several other immune cell types, including NK cells and γδ T cells, are being successfully explored for cancer immunotherapy [202][203][204][205].…”

Section: Discussionmentioning

confidence: 99%

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

et al. 2023

View full text Add to dashboard Cite

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chimeric antigen receptors (CARs) reprogram immune cells to target and eliminate cancer. However, CAR T cell therapy's success depends on the balance between effective anti-tumor activity and minimizing harmful side effects. To improve CAR T cell therapy outcomes and mitigate associated toxicities, scientists from different fields are cooperating in developing next-generation products using the latest molecular cell biology and synthetic biology tools and technologies. The immunotherapy field is rapidly evolving, with new approaches and strategies being reported at a fast pace. This comprehensive literature review aims to provide an up-to-date overview of the latest developments in controlling CAR T cell activity for improved safety, efficacy, and flexibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

et al. 2023

View full text Add to dashboard Cite

show abstract

“…γδ T cells provide themselves with a valid alternative to overcome these limits thanks to their unique features ( 68 ). Indeed, they recognize conserved antigens widely expressed on stressed and tumor cells without the need for MHC restriction and costimulatory molecules.…”

Section: How To Use γδ T Cells For Immunotherapeutic Protocolsmentioning

confidence: 99%

γδ T cells and their clinical application in colon cancer

et al. 2023

View full text Add to dashboard Cite

In recent years, research has focused on colorectal cancer to implement modern treatment approaches to improve patient survival. In this new era, γδ T cells constitute a new and promising candidate to treat many types of cancer because of their potent killing activity and their ability to recognize tumor antigens independently of HLA molecules. Here, we focus on the roles that γδ T cells play in antitumor immunity, especially in colorectal cancer. Furthermore, we provide an overview of small-scale clinical trials in patients with colorectal cancer employing either in vivo activation or adoptive transfer of ex vivo expanded γδ T cells and suggest possible combinatorial approaches to treat colon cancer.

show abstract

“…Not only do unmodified Vδ2 T cells represent an attractive source for adoptive cell immunotherapy and for developing "off-the-shelf" Vδ2 T-based therapeutic products, but also genetic engineering strategies can be applied to further enhance the cytotoxicity and affinity of these cells towards specific tumor targets, either as vehicles for chimeric antigen receptors (CARs) or αβ T cell-derived TCRs or as bispecific T cell engagers (BiTEs). These specific applications have all been extensively described in several recent reviews [77][78][79][80][81][82][83][84].…”

Section: Vδ2 T Cells As a Source For Cancer Immunotherapiesmentioning

confidence: 99%

NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy

Cazzetta

Depierreux

Colucci

et al. 2023

Cancers

View full text Add to dashboard Cite

Immune regulation has revolutionized cancer treatment with the introduction of T-cell-targeted immune checkpoint inhibitors (ICIs). This successful immunotherapy has led to a more complete view of cancer that now considers not only the cancer cells to be targeted and destroyed but also the immune environment of the cancer cells. Current challenges associated with the enhancement of ICI effects are increasing the fraction of responding patients through personalized combinations of multiple ICIs and overcoming acquired resistance. This requires a complete overview of the anti-tumor immune response, which depends on a complex interplay between innate and adaptive immune cells with the tumor microenvironment. The NKG2A was revealed to be a key immune checkpoint for both Natural Killer (NK) cells and T cells. Monalizumab, a humanized anti-NKG2A antibody, enhances NK cell activity against various tumor cells and rescues CD8 αβ T cell function in combination with PD-1/PD-L1 blockade. In this review, we discuss the potential for targeting NKG2A expressed on tumor-sensing human γδ T cells, mostly on the specific Vδ2 T cell subset, in order to emphasize its importance and potential in the development of new ICI-based therapeutic approaches.

show abstract

Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy

Cited by 25 publications

References 150 publications

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

γδ T cells and their clinical application in colon cancer

NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy

Contact Info

Product

Resources

About